LifeSci Healthcare Fund

An unconstrained biotech/healthcare portfolio, this AlphaCentric Fund focuses on disruptive life sciences innovators, robust cash flow/revenue growth companies, and direct funding through private placements, IPOs, and other structured transactions. The portfolio manager is co-inventor of an FDA approved therapeutic and eight drug patents. The Fund objective is long-term capital appreciation.

fund management

Mark G. Charest, Ph.D.

LifeSci Fund Management

Mark G. Charest, Ph.D. has been Portfolio Manager of the Fund since inception. Prior to that, Mr. Charest enjoyed a 12+ year career as an investor at several specialized $1B+ AUM healthcare funds. He also led a Medicinal Chemistry Lab at the Novartis Institutes for BioMedical Research, focused on Oncology drug discovery. Mr. Charest is a co-inventor on 8 drug patents, including an FDA-approved therapeutic. A Kauffman Fellow and National Science Foundation Graduate Research Fellow, Mr. Charest earned a Ph.D. and M.S. in Chemistry and Chemical Biology from Harvard University.
Fund Overview
Ticker LYFIX LYFAX LYFCX LYFAX
Share Class Class I Class A Class C Class A w/ Sales Load
CUSIP 62827P337 62827P352 62827P345 62827P352
Inception Date 11/29/2019 11/29/2019 11/29/2019 11/29/2019
As of Date 3/28/2024 3/28/2024 3/28/2024 3/28/2024
Daily NAV 12.83 12.73 12.47 12.73
NAV Change -0.04 -0.04 -0.04 -0.04
% NAV Change -0.31% -0.31% -0.32% -0.31%

The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above.  Nav data reflects price of 1 share, as well as price change and percent change since the previous trading day.

FACT SHEET

PRESENTATION

Quarterly Fund Performance
Data as of quarter end 3/31/2024
Share Class 1 Month 3 Months 6 Months YTD 1 Year 3 Years Annualized 5 Years Annualized 10 Years Annualized Since Inception Annualized
Class I 0.08% -0.77% 2.69% -0.77% -0.56% 0.04% N/A N/A 11.39%
Class A 0.08% -0.78% 2.63% -0.78% -0.79% -0.21% N/A N/A 11.16%
Class C 0.08% -0.95% 2.27% -0.95% -1.50% -0.96% N/A N/A 10.53%
Class A w/Sales Load -5.70% -6.47% -3.29% -6.47% -6.47% -2.16% N/A N/A 9.65%

The performance data quoted represents past performance, past performance does not guarantee future results, the investment return and principal value of an investment will fluctuate so that when redeemed, it may be worth more or less than their original cost, and current performance may be lower or higher than the performance data quoted.

The maximum sales charge for Class “A” Shares is 5.75%. The Fund’s total operating expenses are 2.00%, 2.75%, and 1.75% for the Class A, C, and I Shares respectively.

The advisor has contractually agreed to waive fees and/or reimburse expenses to maintain the Fund’s total annual operating expense ratio at 1.65%, 2.40% and 1.40% for Class A shares, Class C shares and Class I shares, respectively, excluding 12b-1 fees through July 31, 2024.

Current Fund Performance
Data as of 3/28/2024
Share Class 1 Month 3 Months 6 Months YTD 1 Year 3 Years Annualized 5 Years Annualized 10 Years Annualized Since Inception Annualized
Class I -1.99% -1.31% 2.22% -0.77% 1.66% 0.12% N/A N/A 11.42%
Class A -2.00% -1.39% 2.15% -0.78% 1.44% -0.12% N/A N/A 11.18%
Class C -2.04% -1.50% 1.78% -0.95% 0.74% -0.87% N/A N/A 10.55%
Class A w/Sales Load -7.62% -7.08% -3.72% -6.47% -4.42% -2.08% N/A N/A 9.67%

The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above.

the goods

LYFIX

POSITIVELY FUNDAMENTAL

Important Risk Information

The Fund may be susceptible to an increased risk of loss, including losses due to adverse occurrences affecting the Fund more than the market as a whole because the Fund’s investments are concentrated in the biotech, pharmaceutical, healthcare facilities and other life science services. Companies in the healthcare sector, including drug and biotech-related companies, may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the governments and regulatory authorities.

Please see the prospectus for all of the principal risks of investing in the Fund. Mutual Fund Investing involves additional risk, principal loss is possible. Investment in the Fund(s) is subject to investment risks, including, without limitation, concentration risk, equity risk, market risk, management risk, small company risk, mid cap stock risk, large redemption risk. Funds that invest in small and mid cap stocks are often more volatile than large cap stocks. Smaller companies generally face higher risks due to their limited product lines, markets and financial resources.

For more information about the Funds, including their objectives, charges, expenses and risks (including more information about the risks listed above), please read the funds’ prospectus.

FACT SHEET
FUND PRESENTATION
QUARTERLY COMMENTARY
WHITE PAPERS + INSIGHTS
SUMMARY PROSPECTUS
PROSPECTUS
SAI
ANNUAL REPORT
SEMI-ANNUAL REPORT
XBRL
HOLDINGS – Dec 2023
HOLDINGS – June 2023
CAPITAL GAINS

Ready to get started?

CONTACT US BELOW OR FIND OUR FORMS HERE!